Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 2Sarcoma 1Plasma cell 1Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 967Precursor Cell Lymphoblastic Leukemia-Lymphoma 585Leukemia, Lymphocytic, Chronic, B-Cell 555Leukemia 486Myelodysplastic Syndromes 375Lymphoma, Non-Hodgkin 347Lymphoma 297Lymphoma, Mantle-Cell 263Hematologic Neoplasms 260Lymphoma, Follicular 256Lymphoma, Large B-Cell, Diffuse 253Burkitt Lymphoma 232Lymphoma, B-Cell, Marginal Zone 227Recurrence 216Hodgkin Disease 182Multiple Myeloma 172Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 159Lymphoma, Large-Cell, Immunoblastic 158Leukemia, Myelomonocytic, Chronic 153Leukemia, Myelogenous, Chronic, BCR-ABL Positive 147Waldenstrom Macroglobulinemia 123Lymphoma, T-Cell, Cutaneous 116Neoplasms 112Lymphoma, Large-Cell, Anaplastic 111Blast Crisis 105Congenital Abnormalities 104Immunoblastic Lymphadenopathy 98Mycosis Fungoides 97Sezary Syndrome 96Myeloproliferative Disorders 92

Interventions

ibrutinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Multi-centric Castleman's Disease × Other hematologic neoplasm × Clear all
NCT02109224 2015-08-20

Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection

National Cancer Institute (NCI)

Phase 1 Terminated
72 enrolled
LymphoidOther hematologic neoplasmPlasma cell

Multi-centric Castleman's Disease, Burkitt Lymphoma, Leukemia, Hairy Cell, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Leukemia, Lymphocytic, Chronic, B-Cell, HIV Infections, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡